A meta-analysis of 39 trials and 85,755 patients found a modest but non-significant trend toward reduced asthma incidence with GLP-1 drugs, with light-molecular-weight GLP-1 agonists showing a significant 35% reduction.
35% asthma reductionwith light-molecular-weight GLP-1 agonists, though the overall GLP-1 class showed only a non-significant 9% trend
What the researchers found
GLP-1 receptor-based agonists showed a non-significant 9% asthma risk reduction overall (RR 0.91, 95% CI 0.68-1.24), but light-molecular-weight GLP-1RAs showed a significant 35% reduction (RR 0.65, 95% CI 0.43-0.99, P=0.043).
Why it matters
If GLP-1 drugs can reduce asthma risk in the millions of people taking them for diabetes and obesity, it would be a significant secondary benefit — especially since these conditions frequently overlap and obesity worsens asthma.
The numbers in context
Meta-analysis pooling data from multiple studies across databases examining GLP-1 RA use and asthma outcomes.
How the study worked
Systematic review and meta-analysis of 39 RCTs (85,755 participants) from PubMed, Web of Science, Embase, Cochrane CENTRAL, and ClinicalTrials.gov through July 2023. Used fixed-effects model with subgroup analyses by drug structure, duration, and molecular weight.
Who was studied
Pooled data from studies of GLP-1 RA use in patients with T2DM and/or obesity
What this study cannot tell us
Overall result was not statistically significant. Asthma was typically an incidental finding in diabetes/obesity trials, not a primary endpoint. Weight loss itself could reduce asthma risk. The significant finding for light-molecular-weight GLP-1RAs may reflect subgroup multiplicity. Different GLP-1 drugs and doses were pooled.
How to read the evidence
Moderate evidence: large meta-analysis with nearly 86,000 participants, but the primary finding was not statistically significant and asthma was a secondary outcome in most included trials.
When this study was published
Published in 2024 with data through July 2023. First major meta-analysis examining GLP-1 drugs and asthma risk.
The bigger picture
The anti-inflammatory properties of GLP-1 drugs extend beyond metabolic effects. This meta-analysis provides initial evidence that these peptide drugs may influence airway inflammation, though the overall signal is weak. As GLP-1 drugs are prescribed to more people for longer durations, clearer patterns may emerge — particularly for specific drug subtypes.
Questions still open
- Would a dedicated trial of GLP-1 drugs in asthma patients confirm the potential benefit?
- Why might light-molecular-weight GLP-1 agonists show a stronger effect than larger molecules?
- Is the potential asthma benefit driven by weight loss, anti-inflammatory effects, or direct airway GLP-1 receptor activation?
Common questions
Can GLP-1 drugs help with asthma?
Why might GLP-1 drugs affect asthma?
Read the original research
The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.
Biomedical and environmental sciences : BES, 37(6), 607-616
Citation
Zhang, Meng Qing; Lin, Chu; Cai, Xiao Ling; Jiao, Ruo Yang; Bai, Shu Zhen; Li, Zong Lin; Hu, Sui Yuan; Lyu, Fang; Yang, Wen Jia; Ji, Li Nong. (2024). The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.. Biomedical and environmental sciences : BES, 37(6), 607-616. https://doi.org/10.3967/bes2024.067